BRAF and melanoma: Preclinical and clinical data obtained in BRAFV600E melanoma models and patients indicated that simultaneous and vertical targeting of more than one node along the MAPK/ERK pathway, such as BRAF and MEK, could bypass the resistance to BRAF inhibitors[129,130] and delay the onset of relapse.